EW
Edwards Lifesciences Corp

4,911
Mkt Cap
$48.25B
Volume
6.13M
52W High
$83.25
52W Low
$64.89
PE Ratio
56.11
EW Fundamentals
Price
$82.69
Prev Close
$82.19
Open
$84.50
50D MA
$77.42
Beta
0.69
Avg. Volume
4.5M
EPS (Annual)
$1.46
P/B
4.58
Rev/Employee
$344,272.15
Loading...
Loading...
News
all
press releases
Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
Exploring Analyst Estimates for Edwards Lifesciences (EW) Q3 Earnings, Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Zacks·1d ago
News Placeholder
Successful Patient Outcomes Demonstrated With Edwards SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025
Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm...
Business Wire·2d ago
News Placeholder
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025
Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior...
Business Wire·2d ago
News Placeholder
Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
News Placeholder
Will SYK's Q3 Results Reflect MedSurg Strength & Rebound in Orthopaedics?
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
Zacks·5d ago
News Placeholder
Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
Zacks·6d ago
News Placeholder
Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, and will host a conference call...
Business Wire·6d ago
News Placeholder
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW Rosen Law Firm Announces Investigation of Breaches of...
PR Newswire·7d ago
News Placeholder
WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?
West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.
Zacks·12d ago

Latest EW News

View

Advertisement|Remove ads.

Advertisement|Remove ads.